scholarly journals Ablación percutánea por radiofrecuencia en metástasis óseas dolorosas. [Percutaneous radiofrequency ablation in painful bone metastases.]

10.15417/373 ◽  
2015 ◽  
Vol 80 (3) ◽  
pp. 164
Author(s):  
German Garabano ◽  
Gerardo Sola ◽  
Ignacio Fita ◽  
Pablo Sarmiento ◽  
Hernan Del Sel
Keyword(s):  
Radiofrequency Ablation ◽  
Bone Metastases ◽  
Percutaneous Radiofrequency Ablation ◽  
Painful Bone Metastases ◽  
Metástasis Óseas

<p><strong>Introducción:</strong> Existen diferentes modalidades de tratamiento para las metástasis (mtts) óseas y el dolor generado por estas, con diferentes resultados. La ablación percutánea por radiofrecuencia (APRF) guiada por tomografía es una de ellas. El objetivo de este reporte fue evaluar retrospectivamente los resultados iniciales utilizando la APRF, focalizando en el alivio del dolor, mostrando detalles de la técnica quirúrgica.</p><p><strong>Materiales:</strong> se trataron 18 pacientes con un promedio de edad de 59,2 anos y un seguimiento de 15 meses. Nueve mtts se ubicaron en fémur, 4 en raquis dorsal / lumbar, 3 en escápula y 2 en Ilíaco, siendo su origen el Ca de Mama en 7 casos, pulmón en 4, Rinon en 4 y 3 en Tiroides. Las mtts en raquis se encontraron a mas de 10mm del conducto medular y las de huesos largos presentaron bajo riesgo de fractura. El dolor fue evaluado mediante la Escala Visual Análoga en el preoperatorio, a los 2, 7 y 30 días, y luego a los 3 y 6 meses. A todos se les realizo APRF guiada por tomografía con el equipo Valleylab utilizando la aguja Rita para lesiones &gt; 3cm o CoolTip para las &lt;3cm.</p><p><strong>Resultados:</strong> la puntuación del dolor preoperatorio fue de 8,33 en promedio, pasando a 5 a la semana de la ablación. Al mes fue de 2 puntos, resultando igual a los 3 y 6 meses con una puntuación de 1. El procedimiento tubo excelente tolerancia y no hubieron complicaciones. Hubieron dos recidivas a las que se les realizó una Endoprótesis no convencional de fémur proximal y de rodilla respectivamente, evolucionando favorablemente.</p><p><strong>Conclusión:</strong> la APRF guiada por tomografía impresiona una herramienta prometedora, sencilla y eficaz en el tratamiento de estas lesiones, logrando un excelente control del dolor con muy buena tolerancia por parte del paciente.</p><p> </p>

Radiofrequency Ablation Therapy Combined with Cementoplasty for Painful Bone Metastases: Initial Experience

2005 ◽  
Vol 28 (5) ◽  
pp. 578-583 ◽  
Author(s):  
Naoyuki Toyota ◽  
Akira Naito ◽  
Hideaki Kakizawa ◽  
Masashi Hieda ◽  
Nobuhiko Hirai ◽  
...  
Keyword(s):  
Radiofrequency Ablation ◽  
Bone Metastases ◽  
Initial Experience ◽  
Ablation Therapy ◽  
Radiofrequency Ablation Therapy ◽  
Painful Bone Metastases

Radiofrequency ablation for palliative treatment of osseous metastases results in rapid, significant, and durable improvements in pain relief and quality of life: Results from the OPuS One trial.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 12086-12086
Author(s):  
Jason Levy ◽  
Elizabeth David ◽  
Thomas Hopkins ◽  
Jonathan Morris ◽  
Nam D. Tran ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Radiofrequency Ablation ◽  
Pain Relief ◽  
Bone Metastases ◽  
Pain Score ◽  
Palliative Treatment ◽  
Vertebral Augmentation ◽  
Painful Bone Metastases ◽  
Treated Site

12086 Background: Patients with bone metastases may experience pain and decreased quality of life. Standard of care therapies such as radiation therapy could take weeks for pain relief and carry a risk of radiation induced fracture. Minimally invasive percutaneous radiofrequency ablation (RFA) have been shown in small observational studies to be an alternative treatment for bone metastases. We report the results of the OPuS One trial evaluating RFA for the palliative treatment of patients with painful bone metastases. Methods: OPuS One (NCT03249584) was a multicenter prospective trial. 218 subjects with painful bone metastases (≥ 4/10 worst pain scores, Brief Pain Inventory [BPI], at target treated site) were enrolled from 15 sites. RFA was performed under image guidance at one or two locations. Vertebral augmentation was followed based on physician’s discretion. Subjects’ pain (BPI) and quality of life (EQ-5D) scores were calculated in subjects at three days, one week, and one, three, six, and 12 months post RFA. Rate of complete (0 pain score at treated site with no concomitant analgesic increase) and partial responders (≥ 2 pain score reduction without analgesic increase or analgesic reduction of ≥ 25% from baseline) were calculated. Device-, procedure-, and/or therapy-related adverse events (AEs) were collected. Results: 206 subjects, 113 (55%) female and 93 (45%) males (mean age was 63.7 years) were treated with RFA. Most common primary cancers were breast (23%), lung (23%), and kidney (10%). 184 (89%) subjects were treated for metastatic lesions involving the thoracolumbar spine and 22 (11%) subjects were treated for iliac crest, periacetabulum, sacrum or mixed vertebral and pelvic location. 99% (262/264) of RFA procedures were technically successful and 97% were followed by vertebral augmentation. Subjects reported significant improvement in worst pain from baseline at 7.8 to 5.5, 4.7, 3.6, 3.2, 2.4, and 2.6 at three days, one week and one, three, six, and 12 months post RFA, respectively (p < 0.0001 for all visits). Significant improvements were also seen in average pain (p < 0.0001 for all visits), pain interference (p < 0.0001 for all visits), and quality of life scores (p < 0.0001 for all visits). Overall response rates were 53%, 58%, 61%, 63%, 70%, and 75% at three days, one week, one month, three months, six months, and twelve months post RFA, respectively. Six AEs were reported with three as serious: intra-abdominal fluid collection, pneumonia and respiratory failure. 82 deaths were reported during the study, none were related to the device, therapy, and/or procedure. No skeletal related events were reported. Conclusions: In a large prospective multicenter trial, OPuS One, RFA provided rapid, significant, and durable improvements in pain relief and quality of life up to 12 months. Clinical trial information: NCT03249584.

Phase I/II Study of Radiofrequency Ablation for Painful Bone Metastases: Japan Interventional Radiology in Oncology Study Group 0208

2018 ◽  
Vol 41 (7) ◽  
pp. 1043-1048
Author(s):  
Noboru Tanigawa ◽  
Yasuaki Arai ◽  
Koichiro Yamakado ◽  
Takeshi Aramaki ◽  
Yoshitaka Inaba ◽  
...  
Keyword(s):  
Interventional Radiology ◽  
Radiofrequency Ablation ◽  
Phase I ◽  
Bone Metastases ◽  
Study Group ◽  
Painful Bone Metastases
Sign in / Sign up

Export Citation Format

Share Document